|
시장보고서
상품코드
2128446
처방용 VR 치료제 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)Prescription VR Therapeutics Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034 |
||||||
처방용 VR 치료제 시장 성장요인
세계 처방용 VR 치료제 시장은 2025년에 1,210만 달러 규모를 기록했으며, 2026년 2,350만 달러에서 2034년에는 3억 7,130만 달러로 확대되어, 예측 기간 동안 41.2%라는 놀라운 연평균 성장률(CAGR)을 기록할 것으로 전망됩니다. 북미는 조기 규제 당국의 승인, 선진적인 의료 인프라, 강력한 보험 환급 정책, 그리고 처방용 디지털 치료제의 채택 확대에 힘입어 2025년에는 93.38%의 시장 점유율을 차지하며 세계 시장을 선도했습니다.
처방전이 필요한 VR 치료제는 만성 통증, 정신 질환, 신경 질환, 재활 요구 및 기타 질환을 치료하기 위해 의료 전문가가 처방하는, FDA의 규제 대상인 가상현실(VR) 소프트웨어 솔루션을 말합니다. 일반 소비자를 대상으로 하는 VR 애플리케이션과 달리, 이러한 플랫폼은 임상적으로 검증되었으며, 몰입형 증거 기반 치료를 통해 환자의 예후를 개선하도록 설계되었습니다. 만성 질환 유병률의 증가, 비침습적 치료법에 대한 선호도 상승, 디지털 헬스케어 인프라의 확대, 그리고 규제 당국의 수용 확대가 세계 시장 성장을 가속화하고 있습니다.
시장 동향
인공지능(AI)을 활용한 개인 맞춤화는 처방용 VR 치료제 시장에서 가장 영향력 있는 동향 중 하나로 부상하고 있습니다. 최신 VR 치료 플랫폼에서는 AI 알고리즘, 원격 모니터링 기능, 실시간 환자 분석 기능을 통합하여 환자의 경과 및 임상 결과에 따라 치료 세션을 개별화하는 추세가 점점 더 확대되고 있습니다.
이러한 플랫폼은 통증 강도, 치료 순응도, 증상 개선, 기능 회복 및 환자 참여도 등 귀중한 환자 데이터를 수집합니다. 이러한 데이터를 통해 의료 제공자는 치료 계획을 최적화하는 동시에 가치 기반 의료 모델을 지원할 수 있게 됩니다. AI를 활용한 디지털 치료제에 대한 투자 증가와 임상 검증 연구의 확대가 시장 도입을 더욱 촉진하고 있습니다.
시장 촉진요인
만성 질환의 유병률 상승이 시장 성장을 이끄는 주요 요인입니다. 근골격계 질환, 만성 통증, 불안 장애, 우울증, 신경 질환 및 재활에 대한 수요가 증가함에 따라 비침습적 디지털 치료법에 대한 강력한 수요가 발생하고 있습니다.
처방에 기반한 VR 치료법은 약물 의존성을 수반하지 않는 몰입형 치료를 제공하여 통증 관리, 행동 건강, 재활 및 환자 참여도 향상에 기여하고 있습니다. AppliedVR, Smileyscope, Floreo, MindMaze 등의 기업들이 조사 개발에 지속적으로 투자함에 따라 신제품 출시 및 치료 용도 확대가 이루어지고 있으며, 이는 세계 시장의 성장을 더욱 촉진하고 있습니다.
시장 제약요인
높은 성장 잠재력이 있는 반면, 불투명한 보험 환급 정책은 시장 확대에 있어 큰 과제로 대두되고 있습니다. 처방용 VR 치료법은 소프트웨어, 의료기기, 행동 치료, 원격 모니터링, 디지털 치료법을 결합한 것이기 때문에 보험 환급 및 보험 적용 범위 결정이 더욱 복잡해지고 있습니다.
또한, 치료비에는 VR 헤드셋, 소프트웨어 구독료, 환자 도입 지원, 기술 지원, 지속적인 모니터링 등이 포함되기 때문에 보험 환급 제도가 미비한 지역에서는 환자가 치료를 받기 어려워지고 있습니다.
시장 기회
가치 기반 의료 및 원격 환자 모니터링과의 통합은 큰 성장 기회를 가져옵니다. 의료 제공자들은 측정 가능한 임상 결과를 입증하면서 장기적인 치료 비용을 절감할 수 있는 치료법을 점점 더 찾고 있습니다.
처방전 기반 VR 플랫폼은 원격 모니터링, 치료 순응도 추적, 증상 평가 및 맞춤형 치료 최적화를 뒷받침하는 환자의 상태에 대한 지속적인 데이터를 생성합니다. 의료 당국의 원격 치료 모니터링 프로그램에 대한 인식이 높아짐에 따라 향후 몇 년 동안 상업적 도입이 가속화될 것으로 예상됩니다.
시장의 과제
개발도상국에서의 의료 접근성 제한은 여전히 시장 성장의 주요 장벽 중 하나입니다. 많은 신흥 경제국에서는 선진적인 의료 인프라, 훈련된 의료 인력, 보험 급여 제도, 그리고 디지털 헬스에 대한 인식 부족에 여전히 직면해 있습니다.
그 밖의 과제로는 규제 복잡성, 사이버 보안 우려, 환자 데이터 개인정보 보호 요건, 임상적 타당성 검증, 기존 의료 시스템과의 통합 등이 있습니다. 이러한 요인들로 인해 디지털 치료제에 대한 관심이 높아지고 있음에도 불구하고, 개발도상 지역에서의 대규모 상용화가 더뎌질 가능성이 있습니다.
세분화 분석
유형별:
2025년에는 소프트웨어, 하드웨어, 환자 모니터링, 임상 지원을 결합한 종합적인 VR 치료 플랫폼에 대한 수요가 증가함에 따라, 통합형 처방 VR 치료 시스템 부문이 시장을 주도했습니다. 예측 기간 동안 치료용 소프트웨어 및 콘텐츠 모듈이 가장 빠른 성장세를 기록할 것으로 예상됩니다.
치료 분야별:
통증 관리 부문은 만성 통증 사례의 증가, 정형외과 수술의 증가, 그리고 비약물적 통증 관리 솔루션에 대한 선호도 상승에 힘입어 가장 큰 시장 점유율을 차지했습니다. 불안 장애, 우울증, PTSD 및 관련 장애에 대한 VR 치료의 수용도가 점차 높아짐에 따라, 정신·행동 건강 분야의 응용 분야가 가장 빠른 성장을 이룰 것으로 예측됩니다.
치료 접근법별:
가상현실 노출 요법(VRET)은 몰입형 노출 요법을 통해 불안 장애, PTSD, 공포증 치료에 효과적인 것으로 나타나, 2025년에도 주요 치료 접근법으로서의 위상을 유지했습니다. 인지 행동 치료(CBT)에 기반한 VR 애플리케이션은 예측 기간 동안 강력한 성장을 보일 것으로 전망됩니다.
케어 환경별:
환자들이 편의성이 높은 재택 치료 솔루션을 점점 더 선호함에 따라, 재택 케어 분야가 시장을 주도했습니다. 원격 모니터링 기능, 맞춤형 치료 세션, 그리고 환자의 치료 순응도 향상으로 인해 처방전 기반 재택 VR 치료법의 보급이 지속적으로 촉진되고 있습니다.
지역별 전망
북미는 계속해서 최대의 지역 시장으로, 2025년에는 1,130만 달러에 달할 것으로 전망됩니다. FDA의 강력한 규제 지원, 보험 환급 제도의 확충, 선진적인 의료 인프라, 그리고 디지털 헬스의 높은 보급률이 계속해서 이 지역의 성장을 견인하고 있습니다. 미국은 처방용 VR 치료법이 널리 수용되고 보험 적용 범위가 확대됨에 따라 최대 국가별 시장이 되었습니다.
유럽은 예측 기간 동안 두 번째로 높은 성장률을 보일 것으로 예상됩니다. 의료비 증가, 디지털 헬스 투자 확대, 지원적인 규제 조치, 그리고 비침습적 치료법에 대한 인식 제고가 해당 지역의 시장 확대에 기여하고 있습니다.
아시아태평양은 3위 지역 시장으로 부상할 것으로 예측됩니다. 만성 질환 유병률의 상승, 의료 인프라의 개선, 의료 디지털화의 진전, 그리고 중국, 일본, 인도 등 국가에서의 첨단 의료 기술 보급 확대가 계속해서 매력적인 성장 기회를 창출하고 있습니다.
라틴아메리카 및 중동 및 아프리카에서는 공공 의료 투자의 증가와 임상적 유효성이 입증된 디지털 치료법에 대한 인식 제고에 따라 완만한 성장이 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 처방용 VR 치료제 시장 분석, 인사이트, 예측, 2021-2034년
제6장 북미의 처방용 VR 치료제 시장 분석, 인사이트, 예측, 2021-2034년
제7장 유럽의 처방용 VR 치료제 시장 분석, 인사이트, 예측, 2021-2034년
제8장 아시아태평양의 처방용 VR 치료제 시장 분석, 인사이트, 예측, 2021-2034년
제9장 라틴아메리카의 처방용 VR 치료제 시장 분석, 인사이트, 예측, 2021-2034년
제10장 중동 및 아프리카의 처방용 VR 치료제 시장 분석, 인사이트, 예측, 2021-2034년
제11장 경쟁 분석
KSM 26.09.16Growth Factors of prescription VR therapeutics Market
The global prescription VR therapeutics market was valued at USD 12.1 million in 2025 and is projected to grow from USD 23.5 million in 2026 to USD 371.3 million by 2034, registering a remarkable CAGR of 41.2% during the forecast period. North America dominated the global market with a 93.38% market share in 2025, driven by early regulatory approvals, advanced healthcare infrastructure, strong reimbursement initiatives, and increasing adoption of prescription digital therapeutics.
Prescription VR therapeutics are FDA-regulated virtual reality software solutions prescribed by healthcare professionals to treat chronic pain, mental health disorders, neurological conditions, rehabilitation needs, and other medical conditions. Unlike consumer VR applications, these platforms are clinically validated and designed to improve patient outcomes through immersive, evidence-based therapies. Rising prevalence of chronic diseases, increasing preference for non-invasive treatment methods, expanding digital healthcare infrastructure, and growing regulatory acceptance are accelerating market expansion worldwide.
Market Trends
Artificial intelligence-enabled personalization is emerging as one of the most influential trends in the prescription VR therapeutics market. Modern VR therapeutic platforms increasingly integrate AI algorithms, remote monitoring capabilities, and real-time patient analytics to personalize treatment sessions according to patient progress and clinical outcomes.
These platforms collect valuable patient data, including pain intensity, therapy adherence, symptom improvement, functional recovery, and engagement levels. Such data enables healthcare providers to optimize treatment plans while supporting value-based healthcare models. Growing investments in AI-driven digital therapeutics and expanding clinical validation studies continue to strengthen market adoption.
Market Drivers
The rising prevalence of chronic diseases is the primary factor driving market growth. Increasing cases of musculoskeletal disorders, chronic pain, anxiety, depression, neurological disorders, and rehabilitation needs are creating strong demand for non-invasive digital treatment alternatives.
Prescription VR therapeutics provide immersive therapy without medication dependency, helping improve pain management, behavioral health, rehabilitation, and patient engagement. Continuous investments in research and development by companies such as AppliedVR, Smileyscope, Floreo, and MindMaze are leading to new product launches and expanding therapeutic applications, further supporting global market growth.
Market Restraints
Despite strong growth potential, uncertain reimbursement policies remain a major challenge for market expansion. Prescription VR therapies combine software, medical devices, behavioral therapy, remote monitoring, and digital therapeutics, making reimbursement and insurance coverage more complex.
In addition, treatment costs include VR headsets, software subscriptions, patient onboarding, technical support, and continuous monitoring, limiting accessibility for patients in regions where reimbursement frameworks remain underdeveloped.
Market Opportunities
Integration with value-based healthcare and remote patient monitoring presents substantial growth opportunities. Healthcare providers increasingly seek therapies capable of demonstrating measurable clinical outcomes while reducing long-term treatment costs.
Prescription VR platforms generate continuous patient performance data that supports remote monitoring, therapy adherence tracking, symptom evaluation, and personalized treatment optimization. Growing recognition of remote therapeutic monitoring programs by healthcare authorities is expected to accelerate commercial adoption over the coming years.
Market Challenges
Limited healthcare access across developing countries remains one of the key barriers to market growth. Many emerging economies continue to face shortages of advanced healthcare infrastructure, trained healthcare professionals, reimbursement mechanisms, and digital health awareness.
Additional challenges include regulatory complexities, cybersecurity concerns, patient data privacy requirements, clinical validation, and integration with existing healthcare systems. These factors may slow large-scale commercialization in developing regions despite growing interest in digital therapeutics.
Segmentation Analysis
By Type:
The integrated prescription VR therapeutic systems segment dominated the market in 2025 due to increasing demand for comprehensive VR treatment platforms combining software, hardware, patient monitoring, and clinical support. Therapeutic software and content modules are expected to register the fastest growth during the forecast period.
By Therapeutic Area:
The pain management segment accounted for the largest market share, supported by rising chronic pain cases, increasing orthopedic surgeries, and growing preference for drug-free pain management solutions. Mental and behavioral health applications are projected to experience the fastest growth as VR therapy becomes increasingly accepted for anxiety, depression, PTSD, and related disorders.
By Therapeutic Approach:
Virtual Reality Exposure Therapy (VRET) remained the leading therapeutic approach in 2025 due to its effectiveness in treating anxiety disorders, PTSD, and phobias through immersive exposure-based treatment. Cognitive Behavioral Therapy (CBT)-based VR applications are expected to witness strong growth throughout the forecast period.
By Care Setting:
The homecare settings segment dominated the market as patients increasingly prefer convenient home-based treatment solutions. Remote monitoring capabilities, personalized therapy sessions, and improved patient adherence continue supporting widespread adoption of home-based prescription VR therapeutics.
Regional Outlook
North America remained the largest regional market, reaching USD 11.3 million in 2025. Strong FDA regulatory support, growing reimbursement initiatives, advanced healthcare infrastructure, and high digital health adoption continue driving regional growth. The U.S. represents the largest national market owing to widespread acceptance of prescription VR therapy and increasing insurance coverage.
Europe is expected to witness the second-fastest growth during the forecast period. Rising healthcare expenditure, increasing digital healthcare investments, supportive regulatory initiatives, and growing awareness of non-invasive therapies are contributing to regional market expansion.
Asia Pacific is projected to emerge as the third-largest regional market. Rising chronic disease prevalence, improving healthcare infrastructure, increasing healthcare digitization, and expanding adoption of advanced medical technologies in countries such as China, Japan, and India continue creating attractive growth opportunities.
Latin America and the Middle East & Africa are expected to record moderate growth as public healthcare investments increase and awareness regarding clinically validated digital therapeutics continues to improve.
Competitive Landscape
The global prescription VR therapeutics market remains relatively concentrated, led by AppliedVR, Inc., Smileyscope, Floreo, MindMaze SA, HypnoVR, BiPSEE Inc., Sana Health Inc., Rocket VR Health, and C2CARE. Leading companies are focusing on FDA approvals, insurance reimbursement, AI-powered therapy personalization, strategic partnerships, mergers and acquisitions, and clinical research to strengthen their competitive positions. Continuous innovation in immersive therapeutic technologies and expanding evidence-based treatment programs are expected to intensify market competition throughout the forecast period.
Conclusion
The global prescription VR therapeutics market is poised for exceptional growth through 2034, driven by increasing adoption of non-invasive digital healthcare solutions, rising chronic disease burden, and expanding regulatory acceptance of virtual reality-based treatments. Strong technological advancements in artificial intelligence, personalized therapy, remote patient monitoring, and value-based healthcare models are expected to transform patient care across multiple therapeutic areas. Although reimbursement limitations and healthcare accessibility challenges remain, ongoing clinical validation, regulatory approvals, and growing investments by healthcare providers and technology companies are expected to sustain long-term market expansion.
Segmentation By Type, Therapeutic Area, Therapeutic Approach, Care Setting, and Region
By Type * Integrated Prescription VR Therapeutic Systems
- Therapeutic Software & Content Modules
- Clinical Management & Support Services
By Therapeutic Area * Pain Management
- Mental & Behavioral Health
- Neurological & Cognitive Disorders
- Rehabilitation & Functional Recovery
- Others
By Therapeutic Approach * Virtual Reality Exposure Therapy (VRET)
- Cognitive Behavioral Therapy (CBT)
- Others
By Care Setting * Hospitals
- Specialty Clinics
- Homecare Settings
- Others
By Region * North America (By Type, By Therapeutic Area, By Therapeutic Approach, By Care Setting, and by Country)
- U.S. (By Type)
- Canada (By Type)
- Europe (By Type, By Therapeutic Area, By Therapeutic Approach, By Care Setting, and by Country/Sub-region)
- U.K. (By Type)
- Germany (By Type)
- France (By Type)
- Italy (By Type)
- Spain (By Type)
- Scandinavia (By Type)
- Rest of Europe (By Type)
- Asia Pacific (By Type, By Therapeutic Area, By Therapeutic Approach, By Care Setting, and by Country/Sub-region)
- China (By Type)
- Japan (By Type)
- India (By Type)
- Australia (By Type)
- Southeast Asia (By Type)
- Rest of Asia Pacific (By Type)
- Latin America (By Type, By Therapeutic Area, By Therapeutic Approach, By Care Setting, and by Country/Sub-region)
- Brazil (By Type)
- Mexico (By Type)
- Rest of Latin America (By Type)
- Middle East & Africa (By Type, By Therapeutic Area, By Therapeutic Approach, By Care Setting, and by Country/Sub-region)
- GCC (By Type)
- South Africa (By Type)
- Rest of the Middle East & Africa (By Type)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Preterm Births, Key Countries/Regions, 2025
- 4.2. Technological Advancements in Prescription VR Therapeutics
- 4.3. New Product Launches, Key Players
- 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships
5. Global Prescription VR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Integrated Prescription VR Therapeutic Systems
- 5.1.2. Therapeutic Software & Content Modules
- 5.1.3. Clinical Management & Support Services
- 5.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 5.2.1. Pain Management
- 5.2.2. Mental & Behavioral Health
- 5.2.3. Neurological & Cognitive Disorders
- 5.2.4. Rehabilitation & Functional Recovery
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Therapeutic Approach
- 5.3.1. Virtual Reality Exposure Therapy (VRET)
- 5.3.2. Cognitive Behavioral Therapy (CBT)
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Care Setting
- 5.4.1. Hospitals
- 5.4.2. Specialty Clinics
- 5.4.3. Homecare Settings
- 5.4.4. Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Prescription VR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Integrated Prescription VR Therapeutic Systems
- 6.1.2. Therapeutic Software & Content Modules
- 6.1.3. Clinical Management & Support Services
- 6.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 6.2.1. Pain Management
- 6.2.2. Mental & Behavioral Health
- 6.2.3. Neurological & Cognitive Disorders
- 6.2.4. Rehabilitation & Functional Recovery
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Therapeutic Approach
- 6.3.1. Virtual Reality Exposure Therapy (VRET)
- 6.3.2. Cognitive Behavioral Therapy (CBT)
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Care Setting
- 6.4.1. Hospitals
- 6.4.2. Specialty Clinics
- 6.4.3. Homecare Settings
- 6.4.4. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.1.1. By Type
- 6.5.2. Canada
- 6.5.2.1. By Type
- 6.5.1. U.S.
7. Europe Prescription VR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Integrated Prescription VR Therapeutic Systems
- 7.1.2. Therapeutic Software & Content Modules
- 7.1.3. Clinical Management & Support Services
- 7.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 7.2.1. Pain Management
- 7.2.2. Mental & Behavioral Health
- 7.2.3. Neurological & Cognitive Disorders
- 7.2.4. Rehabilitation & Functional Recovery
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Therapeutic Approach
- 7.3.1. Virtual Reality Exposure Therapy (VRET)
- 7.3.2. Cognitive Behavioral Therapy (CBT)
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Care Setting
- 7.4.1. Hospitals
- 7.4.2. Specialty Clinics
- 7.4.3. Homecare Settings
- 7.4.4. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
- 7.5.1.1. By Type
- 7.5.2. Germany
- 7.5.2.1. By Type
- 7.5.3. France
- 7.5.3.1. By Type
- 7.5.4. Spain
- 7.5.4.1. By Type
- 7.5.5. Italy
- 7.5.5.1. By Type
- 7.5.6. Scandinavia
- 7.5.6.1. By Type
- 7.5.7. Rest of Europe
- 7.5.7.1. By Type
- 7.5.1. U.K.
8. Asia Pacific Prescription VR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Integrated Prescription VR Therapeutic Systems
- 8.1.2. Therapeutic Software & Content Modules
- 8.1.3. Clinical Management & Support Services
- 8.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 8.2.1. Pain Management
- 8.2.2. Mental & Behavioral Health
- 8.2.3. Neurological & Cognitive Disorders
- 8.2.4. Rehabilitation & Functional Recovery
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Therapeutic Approach
- 8.3.1. Virtual Reality Exposure Therapy (VRET)
- 8.3.2. Cognitive Behavioral Therapy (CBT)
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Care Setting
- 8.4.1. Hospitals
- 8.4.2. Specialty Clinics
- 8.4.3. Homecare Settings
- 8.4.4. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. Japan
- 8.5.1.1. By Type
- 8.5.2. Australia
- 8.5.2.1. By Type
- 8.5.3. China
- 8.5.3.1. By Type
- 8.5.4. India
- 8.5.4.1. By Type
- 8.5.5. Southeast Asia
- 8.5.5.1. By Type
- 8.5.6. Rest of Asia Pacific
- 8.5.6.1. By Type
- 8.5.1. Japan
9. Latin America Prescription VR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Integrated Prescription VR Therapeutic Systems
- 9.1.2. Therapeutic Software & Content Modules
- 9.1.3. Clinical Management & Support Services
- 9.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 9.2.1. Pain Management
- 9.2.2. Mental & Behavioral Health
- 9.2.3. Neurological & Cognitive Disorders
- 9.2.4. Rehabilitation & Functional Recovery
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Therapeutic Approach
- 9.3.1. Virtual Reality Exposure Therapy (VRET)
- 9.3.2. Cognitive Behavioral Therapy (CBT)
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Care Setting
- 9.4.1. Hospitals
- 9.4.2. Specialty Clinics
- 9.4.3. Homecare Settings
- 9.4.4. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.1.1. By Type
- 9.5.2. Mexico
- 9.5.2.1. By Type
- 9.5.3. Rest of Latin America
- 9.5.3.1. By Type
- 9.5.1. Brazil
10. Middle East & Africa Prescription VR Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Integrated Prescription VR Therapeutic Systems
- 10.1.2. Therapeutic Software & Content Modules
- 10.1.3. Clinical Management & Support Services
- 10.2. Market Analysis, Insights and Forecast - By Therapeutic Area
- 10.2.1. Pain Management
- 10.2.2. Mental & Behavioral Health
- 10.2.3. Neurological & Cognitive Disorders
- 10.2.4. Rehabilitation & Functional Recovery
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By Therapeutic Approach
- 10.3.1. Virtual Reality Exposure Therapy (VRET)
- 10.3.2. Cognitive Behavioral Therapy (CBT)
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Care Setting
- 10.4.1. Hospitals
- 10.4.2. Specialty Clinics
- 10.4.3. Homecare Settings
- 10.4.4. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC
- 10.5.1.1. By Type
- 10.5.2. South Africa
- 10.5.2.1. By Type
- 10.5.3. Rest of Middle East & Africa
- 10.5.3.1. By Type
- 10.5.1. GCC
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. AppliedVR, Inc.
- 11.2.2. Smileyscope
- 11.2.3. Floreo
- 11.2.4. Mindmaze SA
- 11.2.5. HypnoVR
- 11.2.6. BiPSEE Inc.
- 11.2.7. Sana Health Inc
- 11.2.8. Rocket VR Health
- 11.2.9. C2CARE
